Groundbreaking Milestone as No.7 Reveals World-First Scientific Innovation

Created with the University of Manchester, the super-peptide blend harnesses the skin’s natural repair processes

Monday 10 April 2023, UK: No7, the UK’s number one skincare brand[1], today announces the launch of No7 Future Renew; a collection of four skincare products proven to reverse the appearance of multiple signs of skin damage. The range contains a new ‘super peptide’ blend that is proven to harness the skin’s natural repair process and the renewal of over 50 key proteins in skin cells. The super peptide blend – which represents the biggest cosmetic science innovation in No7’s history – contains two brand-new chemical entities, a patent-pending world-first technology that cannot be found in any other product.

No7 Future Renew and its super-peptide blend have been developed following 15 years of research and innovation using scientific methods and approaches that are more akin to medical research and rarely seen in cosmetic product development. The new peptide blend was developed using cutting edge British R&D across several fields of science and technology including advanced robotics, mathematical modelling, bioinformatics, machine learning, cell biology and cosmetic science. 

No7’s new super peptide is set to be one of the most effective and tolerated skincare ingredients on the cosmetic market. Unlike retinoic acid, which is known by dermatologists to cause tolerance challenges such as skin sensitivity and redness, No7's new super peptide is both highly potent and highly tolerated, being suitable even for those with sensitive skin. This paves the way to highly effective skincare being available to even more people.

The new discovery has undergone the most extensive and diverse testing programme in No7’s history - 37 studies on over 4,200 people, including two clinical trials and 23 user trials. More than half (51%) of the total testing group had skin of colour. 

At the heart of the collection is the No7 Future Renew Damage Reversal Serum, clinically proven in a blinded split-face controlled trial to reverse the appearance of multiple signs of skin damage across a range of skin types and tones, including fine lines, wrinkles, lack of luminosity, dryness, uneven skin tone and loss of firmness. 97% of women in the clinical study had improvements in the appearance of multiple (3 or more) visible signs of skin damage. Patent applications have been submitted and are pending for both the new peptides and the delivery system found within the serum.

Dr Mike Bell, Head of Science Research at No7, said:

Skin damage happens throughout our lives and is caused by multiple factors including sun exposure, environmental pollution, stress, sleep, temperature and nutrition.

The new peptide blend effectively tricks the skin into thinking that it has been damaged which leads to renewal of key proteins such as collagen and fibrillin. It therefore supports skin’s natural self-repair mechanisms, targeting signs of cumulative damage both on and under the surface. This is a world-first technology only available from No7. We believe it is going to be a game changer for consumers.

The new super peptide technology has been met with excitement from the global scientific community with the technology being presented at three world leading scientific conferences this Spring including the American Academy of Dermatology (AAD) Annual Conference in Louisiana, the British Society for Investigative Dermatology (BSID) Annual Meeting in Glasgow and the International Societies for Investigative Dermatology (ISID) meeting in Tokyo. 

The No7 Future Renew range will be available nationwide at Boots stores, and from 12th April 2023.


[1] Source: Kantar Total Market | UK | 52 w/e 30th October 2022 | Boots No.7 Value Share of Mass Female/Unisex Skincare.



For all media enquiries and interview requests, please contact the team at Sassy:

Karun Jung


Tel: +44 (0) 7725 940 179 

Andriana Toneva


Tel: +44 (0) 7761 255 487


You may also like


No7’s new skin service uses a dermatologist-grade device, a first to be available nationwide